XSTO
CMH
Market cap160mUSD
, Last price
SEK
Name
Chordate Medical Holding publ AB
Chart & Performance
Profile
Chordate Medical Holding AB (publ), a medical technology company, develops products and solutions for the treatment of chronic migraine and rhinitis in Sweden. It focuses on the ear-nose and throat area. The company was founded in 2005 and is based in Kista, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 665 -31.92% | 976 799.66% | 109 -87.70% | |||||||
Cost of revenue | (1,324) | 1,654 | 21,124 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 1,989 | (678) | (21,015) | |||||||
NOPBT Margin | 299.17% | |||||||||
Operating Taxes | (81) | |||||||||
Tax Rate | ||||||||||
NOPAT | 1,989 | (678) | (20,934) | |||||||
Net income | (27,254) -6.62% | (29,187) 4.45% | (27,943) 28.38% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 21,362 | 33,200 | 65 | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1 | 1 | ||||||||
Net debt | (2,530) | (8,546) | (3,758) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (24,408) | (27,263) | (24,979) | |||||||
CAPEX | (1,102) | (378) | (389) | |||||||
Cash from investing activities | (2,880) | (1,158) | (389) | |||||||
Cash from financing activities | 21,362 | 33,200 | 65 | |||||||
FCF | 1,576 | (796) | (21,064) | |||||||
Balance | ||||||||||
Cash | 2,530 | 8,455 | 3,676 | |||||||
Long term investments | 91 | 82 | ||||||||
Excess cash | 2,496 | 8,497 | 3,752 | |||||||
Stockholders' equity | (16,169) | 345,604 | (248,072) | |||||||
Invested Capital | 25,364 | 6,589 | 259,145 | |||||||
ROIC | 12.45% | |||||||||
ROCE | 21.63% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 1,025 | 224,513 | 415 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 4,208 | 559 | (18,562) | |||||||
EV/EBITDA | ||||||||||
Interest | 7 | 81 | ||||||||
Interest/NOPBT |